Medtronic plc
For the period ended Apr 26, 2024. Filed Jun 20, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Jun 20, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 2. Properties
Medtronic's principal executive office is located in Ireland and is leased by the Company, while its main operational offices are located in the Minneapolis, Minnesota metropolitan area and are owned by the Company.
The Company's total manufacturing and research space is approximately 9.9 million square feet. Approximately 36 percent of the manufacturing or research facilities are owned by Medtronic and the remaining balance is leased. The following is a summary of the Company's largest manufacturing facilities by location:
| Location Country or State | Square Feet (in thousands) |
|---|---|
| Connecticut | 1,138 |
| Puerto Rico | 812 |
| Mexico | 762 |
| China | 708 |
| Minnesota | 568 |
| Ireland | 446 |
| Dominican Republic | 395 |
| Arizona | 294 |
| Switzerland | 283 |
| California | 258 |
| Massachusetts | 250 |
| France | 249 |
| Italy | 230 |
| Colorado | 228 |
Medtronic also maintains sales and administrative offices outside the U.S. at 114 locations in 62 countries. A majority of these locations are leased. The Company is using substantially all of its currently available productive space to develop, manufacture, and market its products. The Company's facilities are well-maintained, suitable for their respective uses, and adequate for current needs.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.